|Dr. Anish Bhatnagar M.D.||Pres, CEO, COO & Director||618.7k||N/A||1970|
|Mr. James H. MacKaness||Chief Financial Officer||392k||N/A||1964|
|Ms. Kristen Yen M.S.||VP of Clinical Operations||317.19k||N/A||1969|
|Ms. Patricia C. Hirano||VP of Regulatory Affairs||343.35k||N/A||1966|
|Mr. Anthony Wondka||Sr. VP & GM||N/A||N/A||1962|
|Dr. Neil M. Cowen M.B.A., Ph.D., MBA||Sr. VP of Drug Devel.||N/A||N/A||N/A|
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Soleno Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.